Pfizer’s new HDL-raising drug will only be available in combination with Lipitor
“Dr. Crawford said that he thought Pfizer was combining the drugs mainly to protect Lipitor from competition. Lipitor, which loses its patent protection in 2010, is the world’s top-selling medicine, with sales of almost $11 billion last year.”
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
